Zoledronic acid, an aminobisphosphonate, prolongs survival of skin allografts

Chia-Yuan Liu, Po-Sheng Yang, Shih-Ping Cheng, Yu-Chuen Huang, Jie-Jen Lee, Chun-Chuan Ko, Hui-Ru Shieh, Yu-Jen Chen


Purpose: Zoledronic acid (ZOL), an effective nitrogen-containing bisphosphonate used to prevent excessive bone loss in clinical practice, has been shown to affect the development of dendritic cells by redirecting differentiation toward a state of atypical maturation. The study was aimed to examine whether ZOL can reduce acute rejection of skin allografts.

Methods: A skin transplantation model using C57BL/6 to BALB/c mice was used. ZOL was injected intraperitoneally into transplant recipients post-surgically. Graft survival, body weight, leukocyte count, hepatic and renal functions were assessed.

Results: ZOL treatment significantly prolonged skin allograft survival in mice. In terms of toxicity, there were no significant differences in body weight, leukocyte count, plasma alanine aminotransferase or creatinine levels between the ZOL-treated and control groups. Histopathology showed that the loss of skin integrity seen in control group was prevented by ZOL treatment. In draining lymph nodes and spleen, the number and clustering extent of mononuclear cells were markedly declined by ZOL treatment. The plasma IL-6 levels were reduced by treatment of ZOL.

Conclusion: ZOL can prolong skin allograft survival without major toxicity.

Full Text:


DOI: http://dx.doi.org/10.25011/cim.v35i4.17144


  • There are currently no refbacks.

Comments on this article

View all comments

© 2007-2017 Canadian Society for Clinical Investigation.
C.I.M. provides open access to all of its content 6 months after the date of publication